EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SOCS3 and IL-6 mRNA levels in PBMC enhance the early prediction for patients with acute-on-chronic hepatitis B liver failure receiving glucocorticoid therapy

Ji-Hui Li, Jing Wang, Han-Xu Zhu, Feng Zhang, Yu-Na Tang, Jing-Wei Wang, Yu-Chen Fan, Hui-Hui Liu, Kai Wang

Frontiers in Cellular and Infection Microbiology · 2025

DOI: 10.3389/fcimb.2025.1571443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Ji-Hui Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Qilu Hospital of Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Suppressor of Cytokine Signaling 3 Protein, Leukocytes, Mononuclear, Interleukin-6, Glucocorticoids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Early prediction is essential in hepatitis B virus-related acute-on-chronic liver failure (ACHBLF) patients receiving glucocorticoid therapy. Interleukin (IL)-6 is the main factor of cytokine storm that occurs in ACHBLF. IL-6 and suppressors of cytokine signaling 3 (SOCS3) may be associated with the prognosis of patients. Peripheral blood mononuclear cells (PBMCs), which are related to the immune response and inflammation of patients, are often used as materials for searching for biomarkers to predict ACHBLF. We aimed to determine serum cytokines levels and to evaluate the prediction value of SOCS3 and IL-6 mRNA levels in PBMC for ACHBLF patients with glucocorticoid therapy.

Methods

Eighty-five patients with ACHBLF, fifty with pre-ACHBLF, fifty with CHB and thirty healthy controls (HCs) were enrolled. ACHBLF and pre-ACHBLF patients (n=135) received standard medical treatments (SMT) and 93 of them treated with glucocorticoids (SMT+GC). Serum cytokines levels, SOCS3 and IL-6 mRNA levels in peripheral blood mononuclear cells (PBMCs) were quantified.

Results

Serum IL-6, IL-1ß, IL-18 and TNF-α levels of non-survivors with glucocorticoid therapy were significantly higher than that of survivors. Serum IL-10 levels in the survivors with glucocorticoid therapy were significantly increased. The analysis of variable importance shows that IL-6 ranks first. SOCS3 and IL-6 mRNA levels in PBMCs were significantly higher in ACHBLF patients than those in pre-ACHBLF patients (p=0.0158; p=0.0421). Non-survivors showed significantly lower SOCS3 levels (p=0.0084) and higher IL-6 levels (p<0 .0001) than survivors in ACHBLF patients. Non-survivors in patients receiving GC therapy had significantly lower SOCS3 levels (p=0.0002) and higher IL-6 levels (p<0 .0001) than survivors.SOCS3 and IL-6 mRNA levels were predictors for 90-day prognosis of patients receiving GC therapy (p=0.003; p=0.002). AUC of MELD score+SOCS3+IL-6 was 0.887 (95%CI, 0.818-0.955) and the optimal cut-off value was 0.29, with sensitivity of 93.3%, specificity of 74.6%. Patients receiving GC therapy with MELD score+SOCS3+IL-6=0.29 had a higher risk of poor prognosis (p<0 .0001). Survival rate in the SMT+GC group was higher than that in the SMT group (p=0.0350).

Discussion

Glucocorticoid treatment could reduce the mortality of ACHBLF. SOCS3 and IL-6 mRNA combined with MELD score could be used to predict for ACHBLF patients receiving glucocorticoid therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Suppressor of Cytokine Signaling 3 ProteinLeukocytes, MononuclearInterleukin-6GlucocorticoidsAcute-On-Chronic Liver FailureRNA, MessengerHepatitis B, ChronicHumansMaleFemaleAdultMiddle AgedBiomarkersPrognosisCytokines

Stichwörter der Autor:innen

IL-6SOCS3acute-on-chronic hepatitis B liver failureglucocorticoidprognosis prediction

Substanzen

Suppressor of Cytokine Signaling 3 ProteinInterleukin-6GlucocorticoidsSOCS3 protein, humanRNA, MessengerBiomarkersIL6 protein, humanCytokines

Autor:innen und Institutionen

  • Department of Hepatology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Hepatology, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China.
  • Institute of Hepatology, Shandong University, Jinan, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, J. H., Wang, J., Zhu, H. X., Zhang, F., Tang, Y. N., Wang, J. W., Fan, Y. C., Liu, H. H., & Wang, K. (2025). SOCS3 and IL-6 mRNA levels in PBMC enhance the early prediction for patients with acute-on-chronic hepatitis B liver failure receiving glucocorticoid therapy. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1571443

Vancouver

Li JH, Wang J, Zhu HX, Zhang F, Tang YN, Wang JW, et al. SOCS3 and IL-6 mRNA levels in PBMC enhance the early prediction for patients with acute-on-chronic hepatitis B liver failure receiving glucocorticoid therapy. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1571443

BibTeX
@article{Li2025,
  author = {Li, Ji-Hui and Wang, Jing and Zhu, Han-Xu and Zhang, Feng and Tang, Yu-Na and Wang, Jing-Wei and Fan, Yu-Chen and Liu, Hui-Hui and Wang, Kai},
  title = {SOCS3 and IL-6 mRNA levels in PBMC enhance the early prediction for patients with acute-on-chronic hepatitis B liver failure receiving glucocorticoid therapy},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  doi = {10.3389/fcimb.2025.1571443}
}
Kostenlos starten →